Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59

Clinical and Experimental Immunology

Volumn 107, Issue 2, 1997, Pages 364-371

  Harris, C L ^a   Kan, K S ^b   Stevenson, G T ^c   Morgan, B P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF WINCHESTER   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

B lymphocytes; CD59; complement; immunotherapy; monoclonal antibodies

Indexed keywords

CD59 ANTIGEN; CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; BONE MARROW PURGING; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; COMPLEMENT ACTIVATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL;

EID: 0031024609     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.1997.265-ce1156.x     Document Type: Article

References (33)

1. George AJT, Spooner. RA, Epenetos AA. Applications of monoclonal antibodies in clinical oncology. Immunol Today 1994; 15:559-61.
2. Kuzel TM, Rosen ST. Antibodies in the treatment of human cancer. Curr Opin Oncol 1994;6:622-6.
3. Rowley SD, Jones RJ, Piantadosi S et al. Efficacy of ex vivo purging tor autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74:501-6.
4. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Engl J Med 1991; 325:1525-33.
5. Gribben JG, Saporito L. Barber M. Blake KW. Edwards RM, Griffin JD, Freedman AS, Nadler LM. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 1992; 80:1083-9.
6. Chao NJ, Stein AS, Long RS, Negrin RS, Amylon MD, Wong RM, Forman SJ, Blume KG. Busulfan/eloposide - initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 1993; 81:319-23.
7. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994: 15:369-96.
8. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF, Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system. J Immunol 1982; 129:184-9.
9. Nicholson-Weller A, Wang CE, Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994; 123:485-91.
10. Fearon DT, Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 1979; 76:5867-71.
11. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991; 9:431-55.
12. Davies A, Lachmann PJ, Membrane defence against complement lysis: the structure and biological properties of CD59. Immunologic Res 1993; 12:258-75.
13. Harris CL, Morgan BP. Characterisation of a glycosyl phosphatidylinositol-anchor deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line. Immunology 1995:86:311-8.
14. Seya T, Okada M, Matsumoto M, Hong KS. Kinoshita T, Atkinson JP. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP). Mol Immunol 1991; 28:1137-47.
15. Kojima A, Iwata K, Seya T, Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 1993; 151: 1519-27.
16. Hatanaka M, Seya T, Matsumoto M, Hara T, Nonaka M, Inoue N, Takeda J, Shimizu A. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines. Biochem J 1996; 314:969-76.
17. Stevenson GT, Glennie MJ, Kan KS, Chemically engineered chimeric and multi-Fab antibodies. In: Clark M, ed. Protein engineering of antibody molecules for prophylactic and therapeutic applications in man. Nottingham: Academic Titles, 1993:127-45.
18. Stevenson GT, Bell AJ, Evans TRJ, French RR, Glennie MJ, Hamblin TJ, Kan KS, Mead GM, Mechanisms in removal of tumour by antibody. Cell Biophysics 1994; 24/25:45-50.
19. 2 antibodies for delivering saporin to lymphoma in vitro and in vivo. Cancer Res 1991; 51:2353-61.
20. Bonardi MA, Bell A, French RR, Gromo G, Hamblin T, Modena D, Tutt AL, Glennie MJ, Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int J Cancer (Suppl.) 1992; 7:73-77.
21. French RR, Hamblin TJ, Bell AJ, Tutt AL, Glennie MJ, Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. Lancet 1995; 346:223-4.
22. 3 derivatives that use cooperative signalling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J Immunol 1991: 147: 60-69.
23. Lane AC, Foroozan S, Glennie MJ, Kowalski-Saunders P, Stevenson GT. Enhanced modulation of antibodies coating guinea pig leukemic cells in vitro and in vivo. The role of Fc gamma R expressing cells. J Immunol 1991; 146:2461-8.
24. Glennie MJ, Stevenson GT. Univalent antibodies kill tumour cells in vitro and in vivo. Nature 1982; 295:712-4.
25. Cobbold SP, Waldmann H, Therapeutic potential of monovalent monoclonal antibodies. Nature 1984; 308:460-2.
26. Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS. Engineered anti-CD38 monoclonal antibodies for immunotherpy of multiple myeloma. J Immunol 1995; 155:925-37.
27. Burton DR. Barbas III CF. Monoclonal Fab fragments from combinatorial libraries displayed on the surface of phage. Immunol Methods 1993:3:1-9.
28. Griffiths A, Hoogenboom HR. Building an in vitro immune system: human antibodies from phage display libraries. In: Clark M. ed. Protein engineering of antibody molecules for prophylactic and therapeutic applications in man. Nottingham: Academic Titles. 1993: 45-64.
29. Burton DR, Barbas III CF. Human antibodies from combinatorial libraries. In: Clark M, ed. Protein engineering of antibody molecules for prophylactic and therapeutic applications in man. Nottingham: Academic Titles. 1993:65-84.
30. Negrin RS, Kiem HP, Schmidt-Wolf ICH, Blume KG, Cleary ML, Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumour cell purging. Blood 1991; 77:654-60.
31. Ghetie M, Vitetta ES, Recent developments in immunotoxin therapy. Curr Opin Immunol 1993; 6:707-14.
32. Vallera DA, Immunotoxins: will their clinical promise be fulfilled? Blood 1994; 83:309-17.
33. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles? Immunol Today 1993; 14:252-9.